A number of research firms have changed their ratings and price targets for Eton Pharmaceuticals (NASDAQ: ETON):
- 11/10/2026 – Eton Pharmaceuticals was downgraded by Zacks Research from “strong-buy” to “hold”.
- 11/10/2026 – Eton Pharmaceuticals had its price target raised by B. Riley Financial from $70.00 to $81.00. They now have a “buy” rating on the stock.
- 11/9/2026 – Eton Pharmaceuticals was upgraded by Weiss Ratings from “hold (c)” to “buy (b-)”.
- 11/6/2026 – Eton Pharmaceuticals had its price target raised by Canaccord Genuity Group from $68.00 to $80.00. They now have a “buy” rating on the stock.
- 11/6/2026 – Eton Pharmaceuticals had its price target raised by HC Wainwright from $70.00 to $80.00. They now have a “buy” rating on the stock.
- 10/15/2026 – Eton Pharmaceuticals had its “buy” rating reaffirmed by Craig Hallum. They now have a $78.00 price target on the stock.
- 10/14/2026 – Eton Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $70.00 price target on the stock.
- 10/12/2026 – Eton Pharmaceuticals was upgraded by Zacks Research from “hold” to “strong-buy”.
- 9/22/2026 – Eton Pharmaceuticals was upgraded by Weiss Ratings from “sell (d-)” to “hold (c)”.
Eton Pharmaceuticals Stock Down 0.8%
Eton Pharmaceuticals stock traded down $0.50 during mid-day trading on Friday, reaching $60.86. 562,529 shares of the company were exchanged, compared to its average volume of 465,023. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.58 and a current ratio of 1.79. The firm has a market cap of $1.76 billion, a P/E ratio of 40.30 and a beta of 0.89. The business has a fifty day moving average of $55.59 and a 200 day moving average of $38.67. Eton Pharmaceuticals, Inc. has a 12-month low of $14.27 and a 12-month high of $70.64.
Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.19. The business had revenue of $57.93 million for the quarter, compared to the consensus estimate of $41.98 million. Eton Pharmaceuticals had a return on equity of 104.82% and a net margin of 35.35%. Research analysts anticipate that Eton Pharmaceuticals, Inc. will post 1.97 earnings per share for the current fiscal year.
Insider Activity at Eton Pharmaceuticals
In other Eton Pharmaceuticals news, Director Paul V. Maier sold 50,000 shares of the business’s stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $59.07, for a total value of $2,953,500.00. Following the completion of the transaction, the director directly owned 59,745 shares in the company, valued at approximately $3,529,137.15. The trade was a 45.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Ipek Erdogan-Trinkaus sold 3,500 shares of the stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $67.41, for a total transaction of $235,935.00. Following the sale, the insider directly owned 4,081 shares of the company’s stock, valued at approximately $275,100.21. The trade was a 46.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 82,666 shares of company stock valued at $5,045,607 over the last quarter. 16.49% of the stock is owned by corporate insiders.
Eton Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited treatment options. Its work includes bringing new medicines and reformulated or otherwise specialized drug products to market. The company’s products include Alkindi Sprinkle, a hydrocortisone granule formulation used to treat adrenal insufficiency, and Eprontia, an oral solution of topiramate used to treat certain seizure disorders and prevent migraines.
Read More
- Five stocks we like better than Eton Pharmaceuticals
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Eton Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
